Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 3/20 | 0.34 |
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25833674 | 0.95 | CYP2D6 (0.36) | ACE2CYP2D6S1PR1S1PR3S1PR5 | |
| SCHEMBL23696753 | 0.90 | ACE2 (0.40) | ACE2CYP2D6S1PR1S1PR3S1PR5 | |
| SCHEMBL25829672 | 0.89 | S1PR1 (0.37) | CYP2D6S1PR1S1PR3S1PR5CA1 | |
| SCHEMBL25730553 | 0.89 | S1PR1 (0.37) | CYP2D6S1PR1S1PR3S1PR5CA1 | |
| SCHEMBL25702619 | 0.89 | CYP2D6 (0.36) | CYP2D6S1PR1S1PR3S1PR5CA1 | |
| SCHEMBL25728828 | 0.89 | USP2 (0.40) | ACE2CYP2D6S1PR1S1PR3S1PR5 | |
| SCHEMBL25829588 | 0.89 | ACE2 (0.41) | ACE2CYP2D6S1PR1S1PR3S1PR5 | |
| SCHEMBL26409616 | 0.88 | S1PR1 (0.38) | CYP2D6S1PR1S1PR3S1PR5CA1 | |
| SCHEMBL25730554 | 0.86 | CYP2D6 (0.43) | ACE2CYP2D6S1PR1S1PR3S1PR5 | |
| SCHEMBL23695856 | 0.86 | CYP2D6 (0.37) | ACE2CYP2D6S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | ACE2 43/4885CYP2D6 474/4885S1PR1 4473/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ACE2 558/4885CYP2D6 3599/4885S1PR1 2230/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ACE2 558/4885CYP2D6 3599/4885S1PR1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.